Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DDD-016
- Development stage
- Preclinical
- Lead developer
- Daya CNS
- Modality
- Small Molecules
01
Overview
DDD-016 is a preclinical small molecule therapeutic being developed by Daya CNS for the treatment of neuropsychiatric disorders, primarily schizophrenia. It is a pentacyclic compound derived from a proprietary non-opioid pyridoindole platform invented by Dr. Parthasarathi Rajagopalan. DDD-016 acts as an antagonist at both 5-hydroxytryptamine receptor 2A (5-HT2A) and Dopamine D2 receptors, showing high affinity for the former and moderate affinity for the latter. The compound was screened against a broad panel of over 80 CNS receptors, transporters, and ion channels to characterize its potential as an antipsychotic agent.
02
Targets
DRD2 (Dopamine D2 Receptor)HTR2A (Serotonin receptor 5-HT2A)
Beyond the preview
Go deeper on DDD-016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DDD-016.